Gracell Biotechnologies Inc. (GRCL) — Financial Flexibility Index
Gracell Biotechnologies Inc. (GRCL) has a Financial Flexibility Index of -0.26x as of March 2021. Free cash flow of $-49.84 Million (operating CF $-63.95 Million minus capex $14.11 Million) represents 0% of total liabilities ($193.62 Million). Explore Gracell Biotechnologies Inc. (GRCL) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Gracell Biotechnologies Inc. Financial Flexibility Index (2018–2022)
Historical Financial Flexibility Index trend for Gracell Biotechnologies Inc. across 5 annual periods.
Annual Financial Flexibility Index for Gracell Biotechnologies Inc. (2018–2022)
Year-by-year free cash flow to debt coverage for Gracell Biotechnologies Inc.. For the full cash flow conversion analysis, see how efficiently does Gracell Biotechnologies Inc. generate cash.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2022 | -10.61x | $-2.98 Billion | $-3.31 Billion | $280.51 Million | ▼ -896.4% |
| 2021 | -1.06x | $-247.81 Million | $-304.55 Million | $232.77 Million | ▼ -30.3% |
| 2020 | -0.82x | $-118.75 Million | $-198.15 Million | $145.29 Million | ▼ -62.4% |
| 2019 | -0.50x | $-78.96 Million | $-135.39 Million | $156.86 Million | ▼ -45.7% |
| 2018 | -0.35x | $-50.50 Million | $-61.86 Million | $146.13 Million | — |